Search results
Results from the WOW.Com Content Network
PDL Biopharma has filed for a liquidation under Delaware Law that was effective January 7 2021. The liquidation plan was approved by shareholders in October 2020.
Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under ...
For premium support please call: 800-290-4726 more ways to reach us
Recently, one of the biggest biotech dividend stocks, PDL BioPharma (NAS: PDLI) , announced that its CFO has left the company for "personal reasons." While investors are always wary of management ...
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Shares of PDL BioPharma (NAS: PDLI) hit a 52-week high on Wednesday. Let's take a look at how it got there and see if clear skies are still in the forecast. How it got hereWith the spinoff of ...
Shares of DepoMed rallied after-hours on Monday after PDL BioPharma announced that it would buy the company's royalty streams on its type 2 diabetes treatments and experimental drugs for $240.5 ...
PDL BioPharma, Inc. (NASDAQ: PDLI) shareholders are going to be scratching their heads trying to figure out what is going on. The company announced after the close on Monday that Bruce Tomlinson ...